Lupin Pharma Stock price:Lupin’s stock rose by 1.26% after receiving tentative approval from the US FDA for Tolvaptan tablets, a generic equivalent of Jynarque® tablets. With estimated annual sales of USD 287 million in the US, this approval allows Lupin to expand its pharmaceutical offerings and manufacture the product at its Nagpur facility, positioning the company for growth in the competitive pharmaceutical market.
Mumbai, India: Lupin, a global pharmaceutical company, saw its shares rise by 1.26% following the announcement of tentative approval from the US Food and Drug Administration (FDA) for Tolvaptan tablets. The stock opened at Rs 1,163.95 on Friday, marking a positive response to the news.
What is Tolvaptan and Why is This Approval Significant?
Tolvaptan tablets are the generic equivalent of Jynarque® tablets, manufactured by Otsuka Pharmaceutical Co., Ltd. This approval allows Lupin to market and produce Tolvaptan tablets in various strengths: 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg. This is a significant development for Lupin as it expands its product offerings in the pharmaceutical market.
Lupin Pharma Stock price: Estimated Annual Sales and Manufacturing Location
Before this approval, Jynarque® had estimated annual sales of USD 287 million in the U.S. According to IQVIA MAT data from August 2023, this indicates a substantial market opportunity for Lupin.
The company plans to manufacture Tolvaptan tablets at its Nagpur facility, ensuring quality and compliance with FDA standards.(Lupin Pharma Stock price)
Here’s a table summarizing the key information about Lupin Pharma:
| Aspect | Details |
|---|---|
| Day’s Range | 1,152.60 – 1,167.95 |
| 52-Week Range | 628.00 – 1,184.70 |
| Previous Close | 1,149.20 |
| Opening Price | 1,159.05 |
| Volume | 569,187 |
| Average Volume (3m) | 1,157,877 |
| 1-Year Change | 54.93% |
| Market Cap | 525.33B |
| Beta | 0.674 |
| P/E Ratio | 54.12 |
| Type | Equity |
| Market | India |
| ISIN | INE326A01037 |
| CUSIP | LUPIN |
| Shares Outstanding | 455,221,984 |
| Revenue | 177.12B |
| EPS (Earnings per Share) | 21.36 |
| Dividend (Yield) | 4 (0.35%) |
| Next Earnings Date | Nov 08, 2023 |
| Technical Sentiments | Summary |
| Analysts | Strong Sell, Strong Buy, Sell, Neutral, Buy |
Lupin’s Growth and Market Impact
Lupin’s consistent efforts to secure approvals for its generic equivalents reflect its commitment to providing cost-effective healthcare solutions. This move not only boosts Lupin’s portfolio but also contributes to the availability of affordable medications for patients in the United States.(Lupin Pharma Stock price)
here’s a table summarizing the key information about Lupin Pharma:
| Aspect | Details |
|---|---|
| Company Name | Lupin Pharmaceuticals |
| Stock Ticker | Lupin Share Price (BSE) |
| Stock Price | Rs 1,162.95 (as of the latest trading session) |
| FDA Approval | Received tentative approval for Tolvaptan tablets |
| Equivalent Drug | Generic equivalent of Jynarque® tablets |
| Manufacturing | To be produced at Lupin’s Nagpur facility |
| Annual Sales | Estimated annual sales of USD 287 million |
Please note that stock prices can fluctuate, and the information provided is based on the date of the article.(Lupin Pharma Stock price)
The approval from the US FDA further strengthens Lupin’s position in the pharmaceutical industry and is expected to have a positive impact on the company’s market performance. For more information, you can refer to the official statement from Lupin regarding this FDA approval.
